ANTIBIOGRAM PROFILING OF HELICOBACTER PYLORI STRAINS AND THE EFFICACY OF BRASSICA CAPITATA AGAINST RESISTANT STRAINS ISOLATED FROM THE PATIENTS SUFFERING FROM GASTRODUODENAL DISEASES IN GUWAHATI, ASSAM

  • Shweta Mahant Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
  • Valentina Gehlot Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
  • Seema Bhatnagar Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
  • Megha Rikhi Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
  • Asish Kumar Mukhopadhyay Department of Bacteriology, National Institutes of Cholera and Enteric Disease, Kolkata, West Bengal, India
  • Sangitanjan Dutta Department of Gastroenterology, Gauhati Medical Collages, Guwahati - 781 024, Assam, India.
  • Anil Agarwal Department of Gastroenterology, Guwahati Medical Collages,Guwahati - 781 024, Assam, India.
  • Kunal Das Max Super Specialty Hospital, Vaishali, Ghaziabad. Uttar Pradesh, India.
  • Rajashree Das Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.

Abstract

 

 Objective: Helicobacter pylori resistance toward commonly used antibiotics is increasing leading to the treatment failure; hence, our aim is to determine the antibiogram susceptibility pattern of H. pylori strains isolated from Guwahati, Assam (Northeast India) and also to test the efficacy of the Brassica capitata against the multi and dual drug-resistant strains of North and Northeast India.

Methods: Minimum inhibitory concentration of different antibiotics was determined by agar dilution method. Disc diffusion method was used to check the efficacy of B. capitata against clarithromycin (CLR), metronidazole (MTZ), and levofloxacin (LEV)-resistant H. pylori strains.

Results: All the H. pylori strains were 100% sensitive to CLR, tetracycline, amoxicillin, and furazolidone. 72.8% of the strains were sensitive toward MTZ and 54.5% were sensitive toward LEV. B. capitata showed good efficacy against the resistant strains of H. pylori of North and Northeast India.

Conclusion: Most of the H. pylori strains from Northeast India were sensitive toward the commonly used antibiotics for the treatment regime. B. capitata is effective against H. pylori infection, suggesting its potential as an alternative therapy, and opens the way for further studies on identification of novel antimicrobial targets of B. capitata.

Keywords: Helicobacter pylori, Antibiotic Resistance, Brassica capitata.

Author Biographies

Shweta Mahant, Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
Amity Institute of Biotechnology
Valentina Gehlot, Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
Amity Institute of Biotechnology
Seema Bhatnagar, Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
Amity Institute of Biotechnology
Megha Rikhi, Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
Amity Institute of Biotechnology
Asish Kumar Mukhopadhyay, Department of Bacteriology, National Institutes of Cholera and Enteric Disease, Kolkata, West Bengal, India
National Institute of Cholera and Enteric Disease, Kolkata, West Bengal
Sangitanjan Dutta, Department of Gastroenterology, Gauhati Medical Collages, Guwahati - 781 024, Assam, India.
Gastroentrology
Anil Agarwal, Department of Gastroenterology, Guwahati Medical Collages,Guwahati - 781 024, Assam, India.
Gastroentrology
Kunal Das, Max Super Specialty Hospital, Vaishali, Ghaziabad. Uttar Pradesh, India.
Gastroentrology
Rajashree Das, Amity Institute of Biotechnology, Amity University, Noida – 201 303, Uttar Pradesh, India.
Amity Institute of Biotechnology

References

1. Blasér MJ. Ecology of Helicobacter pylori in human stomach. J Clin Invest 1997;100:759-62.
2. De Luca A, Iaquinto G. Helicobacter pylori and gastric diseases: A dangerous association. Cancer Lett 2004;213:1-10.
3. Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol 2015;7:455-65.
4. Fallahi GH, Maleknejad S. Helicobacter pylori culture and antimicrobial resistance in Iran. Indian J Pediatr 2007;74:127-30.
5. Dzierzanowska-Fangrat K, Rozynek E, Celinska-Cedro D, Jarosz M, Pawlowska J, Szadkowski A. Antimicrobial resistance of Helicobacter pylori in Poland: A multicentre study. Int J Antimicrob Agents 2005;26:230-4.
6. Poddar U, Yachha SK. Helicobacter pylori in children: An Indian perspective. Indian Pediatr 2007;44:761-70.
7. Phukan RK, Narain K, Zomavia E. Dietry habits and stomach cancer in Mizoram, India. J Gastroenterol 2006;41:418-24.
8. Hoffman JS, Cave DR. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2001;17:30-4.
9. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17:99-109.
10. Nahar S, Mukhopadhyay AK, Khan R, Ahmad MM, Datta S, Chattopadhyay S. Antimicrobial susceptibility of Helicobacter pylori strains isolated from Bangladesh. J Clin Microbiol 2004;42:4856-8, 290.
11. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and levofloxacin in the Netherlands. J Antimicrob Chemother 1999;43:511-5, 294.
12. Toracchio S, Cellini L, Campli ED, Cappello G, Malatesta MG, Ferri A. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;4:1639-43.
13. Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda Mde C, Mendonca S. Analysis of antimicrobial susceptibility and virulence factors in Helicobacterpylori clinical isolates. BMC Gastroenterol 2003;3:20.
14. Siavoshi F, Pourkhajeh AH, Merat SH, Asl-Soleimani H, Heydarian E, Khatibian M. Susceptibility of various strains of H. pylori to selected agents. Arch Iran Med 2000;3:60-3.
15. Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin and tetracycline in Lebanon. Int J Antimicrob Agents 2002;19:155-8.
16. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.
17. Joo YE. Natural product-derived drugs for the treatment of inflammatory bowel diseases. Intestinal Res 2014;12:103-9.
18. Uh M, Kassie F, Rabot S, Grasl-Kraupp B, Chakraborty A, Laky B, et al. Effect of common Brassica vegetables (Brussels sprouts and Red cabbage) on the development of preneoplastic lesions induced by 2-amino-3- methylimidazo [4,5-f] quinoline (IQ) in liver and colon of Fischer 344 rats. J Chromatogr B Anal Technol Biomed Life Sci 2004;802:225-30.
19. Murray MG, Thompson WF. Rapid isolation of high molecular weight plant DNA. Nucleic Acid Res 1980;8:4321-5.
20. Chattopadhyay S, Patra R, Ramamurthy T, Chowdhury A, Santra A, Dhali GK. Multiplex PCR assay for rapid detection and genotyping of Helicobacter pylori directly from biopsy specimens. J Clinn Microbiol 2004;42:2821-4.
21. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version3.1; 2013.
22. Fourth Informational Supplement M100-S14. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: NCCLS; 2004
23. Clinical Laboratory Standard Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved guideline- Second edition. CLSI document M45-A2, Vol. 30. Wayne, PA, USA: CLSI; 2010.
24. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720-41.
25. Bindayna KM. Antibiotic susceptibilities of Helicobacter pylori. Saudi Med J 2001;22:53-7.
26. Singh V, Mishra S, Maurya P, Rao G, Jain AK, Dixit VK, et al. Drug resistance pattern 324 and clonality in H. pylori strains. J Infect Dev Ctries 2009;3:130-6.
27. Datta S, Chattopadhyay S, Patra R, De R, Ramamurthy T, Hembram J. Most Helicobacter pylori strains of Kolkata in India are resistant to MTZ but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther 2005;22:51-7.
28. Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol 2003;18:1373-22, 8.
29. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.
30. Marais A, Bilardi C, Cantet F, Mendz GL, Mégraud F. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 2003;154:137-44.
31. Gehlot V, Mahant S, Mukhopadhyay AK, Das K, De R, Kar P, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from the patients in North India. J Glob Antimicrob Resist 2015;5:51-6.
32. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Roda A, Roda E. Efficacy and tolerability of a short-term low-dose triple therapy for eradication of Helicobacter pylori. Gastroenterology 1993;104:40A.
33. Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol 2014;32:408-13.
34. Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist 2016;6:39-43.
35. Gehlot V, Mahant S, Das R. Most of the Helicobacter pylori isolates are resistant to levofloxacin in North India. Int J Pharm Pharm Sci 2016;8:454-6.
36. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 2009;53:1592-7.
37. Mehrotra S, Jamwal R, Shyam R, Meena DK, Mishra K, Patra R, et al. Anti-Helicobacter pylori and antioxidant properties of Emblica officinalis pulp extract: A potential source for therapeutic use against gastric ulcer. J Med Plants Res 2011;5:2577-83.
38. Chanda S, Gehlot V, Das R, Mahant S, Das K, Singh K, et al. Antimicrobial activity of herbal extract against drug resistant Helicobacter pylori isolates from India. World J Pharm Res 2014;3:1234-43.
39. Gehlot V, Mahant S, VijayraghwanP, Das K, Hoda S, Das R. Therapeutic potential of lichen Parmelia perlata against dual drug-resistant Helicobacter pylori isolates. Int J Pharm Pharm Sci 2016;8:205-8.
40. Carvalho CA, Silva MB, Oliveira TG, Lima JM, Rosa MB. Spectrometric study at different phenologic stages of the cabbage (Brassica oleraceaevar. capitata). Rev Bras Farm 2008;18:249-57.
41. Silva Jr AA, Miura L, Yokoyama S. Cabbage: New summer cultivars. Agrop Catarinense 1988;1(3):47-9.
Statistics
348 Views | 150 Downloads
How to Cite
Mahant, S., V. Gehlot, S. Bhatnagar, M. Rikhi, A. Mukhopadhyay, S. Dutta, A. Agarwal, K. Das, and R. Das. “ANTIBIOGRAM PROFILING OF HELICOBACTER PYLORI STRAINS AND THE EFFICACY OF BRASSICA CAPITATA AGAINST RESISTANT STRAINS ISOLATED FROM THE PATIENTS SUFFERING FROM GASTRODUODENAL DISEASES IN GUWAHATI, ASSAM”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 8, Aug. 2018, pp. 176-80, doi:10.22159/ajpcr.2018.v11i8.25220.
Section
Original Article(s)